BMS’ Opdivo plus LAG-3 antibody relatlimab show promise in melanoma
RELATIVITY-047 trial met primary endpoint of progression-free survival
Read More
Tag: relatlimab
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
